Pandorum Technologies has announced the closing of a USD 18 million in Series B financing round, to advance the clinical development of its disease-modifying, tunable, exosome-based therapies, including Kuragenx, while scaling global manufacturing and expanding operations across the US, Japan and the Middle East.

The round was led by Protons Corporate, with participation from Galentic Pharma, marquee investor Ashish Kacholia, Noblevast Advisory and Avinya Fund, Burman Family and others. Bandana Kankani, adviser and investor, Pandorum, had guided the transaction, optimising the alignment between the investment architecture and company’s value creation.

Founded by Tuhin Bhowmick and Arun Chandru, the company's proprietary platform combines biology, engineering and computation to develop tunable, regenerative exosome therapies that reprogramme pathological tissue states, like inflammation and fibrosis, towards functional recovery.

“Just like the Ship of Theseus, the human body is constantly being rebuilt. Pandorum focuses on restoring biological memory, redefining regenerative medicine at its core. Our approach treats tissue health, disease and degeneration as a navigational challenge within an information-constrained biological landscape. This funding would enable us to translate breakthrough science into programmable, disease-modifying therapies, beginning with single-tissue applications and scaling to multi-tissue repair, aligned with Pandorum’s vision- to heal fast and age slow, said Dr Tuhin Bhowmick, Co-Founder and CEO, Pandorum,” added Dr Tuhin. 

The clinical translation efforts are led by Dr Virender Singh Sangwan from Dr Shroff’s Charity Eye Hospital, New Delhi; Dr Shigeru Kinoshita from Kyoto Prefectural University of Medicine and Dr Ramez Haddadin and Dr Satish Nadig from Northwestern Medicine, Chicago.

“Congratulations to our team for this achievement. Regenerative medicine, particularly for corneal blindness, is a global necessity that knows no borders,” said Arun Chandru, Co-Founder, Pandorum Technologies.

Pandorum’s primary focus is on ocular surface diseases, such as Stevens–Johnson Syndrome and Neurotrophic Keratitis, for which Kuragenx has received US FDA Orphan Drug Designation (ODD). In addition to ophthalmology, it is expanding its tunable platform to address systemic conditions, including inflammatory and degenerative diseases affecting the lung, liver and nervous systems.